|
Group | Condition | Treatment | Effects | Ref |
|
CVD | Stroke/MI | | Decreased level of GSH | [113] |
CVD | MI after cardiac surgery | | GST polymorphism; presence of allele AC | [121] |
CVD | MI/death from some form of CVD | | Decreased level of erythrocyte GPx-1 | [123] |
CVD | Heart transplantation/coronary artery bypass grafting/ aortic valve replacement | | Decreased level of GSH | [120] |
CVD | Cardiac catheterization | Ach (50 mg/min) with GSH (50 mg/min) or saline (50 mg/min) | Vasodilatory effects on coronary arteries and increased blood flow | [112] |
Diabetes/CVD | Type 2 diabetes mellitus/some form of CVD | | Increased values of IMT in Pro/Leu GPx-1 genotype | [94] |
Diabetes/CVD | Diabetes/coronary heart disease | | Decreased level of GSH; increased level of GSSG | [124] |
Diabetes | Type 2 diabetes mellitus | | Decreased levels of GSH and enzymes involved in GSH synthesis; increased level of GSSG and TGF-β | [115] |
Diabetes | Type 2 diabetes mellitus | NAC in a dose 1200 mg/day for 1 month | Increased levels of GSH and GSH : GSSG ratio; decreased levels of VCAM-1 and GSSG | [125] |
Diabetes | Type 2 diabetes mellitus | Oral NAC (600 mg/2x daily/2 weeks) and oral NAC (1200 mg/2x daily/2 weeks) | Unchanged levels of GSH and GSH/GSSG ratio | [126] |
Hypertension | Elderly people with hypertension | | Disturbed level of GSH and enzymes involved in the synthesis of GSH | [118] |
Hypertension | Elderly people with hypertension | Antihypertensive drugs | Increased level of GSH and GSR | [119] |
Hypertension | Hypertension | | Decreased level of GSH; increased level of GSSG | [117] |
Hypertension | Nontreated hypertension | Different antihypertensive therapies for 3 months | Decreased level of OS and GSSG; increased level of GSH | [116] |
Metabolic disorder | Metabolic syndrome | 3 weeks with oral NAC (200 mg/day), oral GSH (450 mg/day), or sublingual GSH (450 mg/day) | Increased levels of GSH and GSH/GSSG ratio in sublingual GSH | [129] |
Control | Healthy adults | Oral GSH in a dose 500 mg twice a day for 4 weeks | Unchanged markers of OS | [128] |
Control | Healthy adults | Oral GSH; low dose (250 mg/day for 6 months) or high dose (1000 mg/day for 6 months) | High-dose group: increased level of GSH in lymphocytes, erythrocytes, and plasma; low-dose group: increased level of GSH in erythrocytes | [111] |
Control | Healthy adults | Orobuccal GSH | Increased level of GSH | [130] |
|